Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic neurological and neurodegenerative conditions often have limited treatment options, and emerging evidence links gut microbiome dysbiosis—particularly low levels of the microbial metabolite butyrate—to impaired gut-brain communication and disease progression.
Solution
Stella Maris Therapeutics develops therapeutics that restore gut-brain health by delivering or enhancing butyrate production in the intestine. Their approach leverages microbiome science to formulate oral or targeted delivery systems that increase local butyrate concentrations, supporting intestinal barrier integrity and modulating neuroinflammatory pathways. By focusing on a non‑conventional, metabolite‑centric strategy, the company aims to provide an adjunct or alternative for patients whose conditions have exhausted conventional pharmacologic options. Preclinical studies evaluate the impact of butyrate augmentation on neural function, while clinical development plans target disorders with a strong gut‑brain axis component, such as Parkinson’s disease, Alzheimer’s disease, and treatment‑resistant depression. The firm also commits a portion of profits to charitable initiatives that promote community health and wellness.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as clinical research organizations, seeking to develop or license gut‑brain therapeutics for neurodegenerative and neuropsychiatric disorders.
Features
- Proprietary formulation technology designed to protect butyrate through the upper gastrointestinal tract and release it in the colon
- Microbiome‑targeted delivery platforms that can be combined with prebiotic or probiotic adjuncts to sustain endogenous butyrate production
- Preclinical validation pipeline assessing gut barrier function, systemic inflammation, and neurobehavioral outcomes
- Scalable oral dosage forms suitable for chronic administration in patient populations with limited treatment alternatives
- Integrated safety monitoring framework aligned with regulatory guidelines for novel microbiome‑derived therapeutics